ClinicalTrials.gg
Active, not recruitingNCT03886324POISEUpdated Aug 17, 2022

POISE I Pilot Study

An interventional study of GIE Medical Drug Coated Balloon in Intestinal Stricture, sponsored by GIE Medical. Active, not recruiting at 1 site in Paraguay. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-08-17.

Sponsored by GIE Medical · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as active, not recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

POISE I study is a feasibility study for evaluating the safety and efficacy of DCB.

Read the detailed description

The study is designed to determine the safety and effectiveness for drug coated balloon (DCB) for treating intestinal strictures.

Up to 15 subjects are planned to be enrolled and treated with the study device at up to 5 clinical sites outside of US. Subjects will be followed up post-treatment to one year and then annually for up to 5 years. The annual follow up after the first year is optional.

02

Conditions studied

  • Intestinal Stricture
03

In context

Constriction, Pathologic

456 studies on the registry are indexed under Constriction, Pathologic; 109 are open to participants now.

This study's enrollment of 10 is below the median of 72 across 295 interventional studies indexed under Constriction, Pathologic.

Browse Constriction, Pathologic studies →

Lead sponsor

GIE Medical is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 and ≤ 80 years.
  2. Subjects for whom the balloon dilation would be chosen in standard practice, and the scope could not pass stricture.
  3. Recurrent to plain balloon dilation with at least 2 previous balloon dilation or stricturotomy sessions and recurrence of intestine obstructive symptoms/signs.
  4. Symptoms of intestinal partial occlusion
  5. Length of stenosis/stricture ≤ 7 cm
  6. Up to 2 discrete strictures.
  7. Ability to undergo periodic endoscopic follow-up.
  8. Voluntary participation and provided written .

Exclusion criteria

Exclusion Criteria:

  1. Pregnancy or breastfeeding or plan to get pregnant in next 12 months.
  2. to endoscopy, anesthesia or deep sedation.
  3. Malignant bowel stricture.
  4. Extrinsic benign bowel stricture due to adhesion.
  5. Stricture complicated with abscess, fistula, ulceration or associated with mesenteric vessel thrombosis
  6. More than 2 stenosis/stricture lesions.
  7. Length of stenosis/stricture > 7 cm.
  8. Stricture not accessible by endoscopy.
  9. Suspected perforation of the gastrointestinal tract
  10. Acute bowel obstruction requiring urgent surgical intervention
  11. Low rectal or anal strictures
  12. Severe coagulation disorders ( \< 70000; > 1.8).
  13. Active systemic infection
  14. Allergy to paclitaxel or any components of the delivery system.
  15. of less than 12 months.
  16. Drug abuse or on chronic therapy for comorbidities.
  17. Unwilling or unable to comply with the follow-up study requirements.
  18. Lacking capacity to provide .
  19. Concurrent medical condition that would affect the investigator's ability to evaluate the patient's condition or could compromise patient safety.
  20. Currently participation in another pre-market drug or medical device clinical study.
  21. Chronic steroid use for any medical conditions unless subject is willing to undergo a 4-week washout and discontinue steroid use.
  22. Currently requiring abdominal radiation therapy
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    DCB Treatment

    Stricture patients treated by DCB

    Combination Product: GIE Medical Drug Coated Balloon

Interventions

  • Combination productGIE Medical Drug Coated Balloon

    Stricture patients treated by DCB

06

What researchers measure

Primary outcomes

  1. Incident of serious balloon dilation-related complications

    Perforation, bleeding requiring endoscopic or surgical interventions or blood transfusion, severe abdominal pain requiring medications, infection requiring hospitalization or IV antibiotics

    Time frame: 30 days

Secondary outcomes

  1. Procedure success

    defined as subjects who were treated with GIE DCB achieved at least one scale improvement of the Endoscopic Obstructive Scale (EOS).

    Time frame: 6 months

  2. Percent subjects with improvement in Endoscopic Obstructive Scale (EOS)

    Analyzed by 1, 2, or 3 scale improvement.

    Time frame: 6 months

  3. Change in obstructive symptoms using the Obstructive Symptom Score (OSS).

    The Obstructive Symptom Score (OSS) is a composite measure of the total number of days of obstructive abdominal pain and the severity over a fourteen-day period using a 5-point Likert scale. (1=no pain, 2=mild, 3=moderate, 4=severe, 5=unbearable).

    Time frame: 30 days, 3 months, 6 months, and 12 months

  4. Number of repeated stricture dilation procedures

    Repeat dilation for stricture recurrence

    Time frame: 30 days, 3 months, 6 months, and 12 months

  5. Procedural technical success

    Successful endoscopic passage followed by successful delivery of the drug-coated balloon to the stricture area without resistance, inflated balloon to the defined diameter, DCB withdraw after deflating balloon without device malfunction.

    Time frame: Time of procedure

07

Study locations

1 site
  • Adventista Hospital
    Asunción, Paraguay
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2019 (actual). Primary completion is estimated for Dec 2025, 82 months after the start.

Of 43 industry-sponsored interventional studies with no phase under Constriction, Pathologic, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 58. This study's planned 82 months is above that.

Counting every sponsor, half of 133 studies reached it within 36 months; a quarter within 18 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2019
First posted
Mar 22, 2019
StartActual
Feb 25, 2019
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2025
Last update
Aug 17, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03886324
Lead sponsor
GIE Medical
Responsible party
Sponsor
First posted
Mar 22, 2019
Start date
Feb 25, 2019
Primary completion
Dec 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Aug 17, 2022

Study contacts

Bo Shen, MD
principal investigator · The Cleveland Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion